Figure 2.

Consecutive PB-MRD and BM-MRD monitoring. Month 0 was defined as the time of diagnosis. 7NB-mRNAs, 7 neuroblastoma-associated mRNAs; 13CRA, 13-cis-retinoic acid; BM-MRD, MRD in bone marrow samples; CR, complete response; GD2, anti-GD2 immunotherapy; HDC, high-dose chemotherapy; IC, induction chemotherapy; LT, local therapy; MRD, minimal residual disease; MRD ratio, PB-MRD/BM-MRD; PB-MRD, MRD in peripheral blood samples; PD, progressive disease; PR, partial response; SC, salvage chemotherapy.